Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Aurobindo Pharma Limited (NSE: AUROPHARMA), ISIN INE406A01037 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
AUROPHARMA last traded at ₹1850.10 (+2.78%), with a 52-week range of ₹1106.00 to ₹1856.10 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 51.88%, FIIs 17.41%, DIIs 24.37%, mutual funds 16.31%.
EquiSense Score (ECS): 84/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.